Home / Auditor changes / InMed Pharmaceuticals Inc.
Filed 2025-06-13 路 Form 8-K 路 Accession 0001213900-25-054315 nano
Price before filing: $2.69 (2025-06-12 close, split/dividend-adjusted)
Market cap at flag: $5.1M (2025-06-13) 路 Latest: $5.8M (2026-10-16)
| Window | INM | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +17.8% | +3.8% | +14.0% | 2025-07-14 |
| 90 days | -19.7% | +9.2% | -29.0% | 2025-09-11 |
| 180 days | -50.9% | +14.5% | -65.5% | 2025-12-10 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"On June 12, 2025, the Audit Committee of the Company's Board of Directors (the " Board ") accepted the resignation of Marcum and approved the engagement of CBIZ as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2025."
Quoted from the filing. Source
The company changed its outside auditor (8-K Item 4.01). A dismissal or resignation, especially near an annual report or with reported disagreements, is a warning sign. Changes caused by audit firms merging are usually routine.
Type: routine (audit-firm merger)
Disagreements reported: no
Why this score: routine: audit firm merged/was acquired; also within 90 days: Going-concern doubt
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.